** Biotech group Oxford Nanopore Technologies ONT.L up as much as 5.7% at 115.9p
** Gene sequencing specialist is now "exposed" to acquisition, CEO and co-founder Gordon Sanghera told FT
** ONT's shares have lost 85% since its peak in 2021
** "Bankers have said it could be attractive to one of the big diagnostics specialists, such as Thermo Fisher Scientific TMO.N or Danaher DHR.N," FT report adds
** As of last close, stock down ~15% this year
(Reporting by Radhika Anilkumar in Bengaluru)
((Radhika.Anilkumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments